EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.418
https://www.valueinhealthjournal.com/article/S1098-3015(22)02622-5/fulltext
Section Title :
Section Order :
12225
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02622-5&doi=10.1016/j.jval.2022.09.418